01542nas a2200313   4500000000100000008004100001260001300042653001200055653001500067653001900082653001100101653000900112653002300121653001200144653001000156653000900166653002400175653002500199653001400224653001400238653001300252100001500265700001500280245018600295300001000481490000700491520071600498022001401214       1994                            d  c1994 Apr10aAnimals10aArmadillos10aDrug Synergism10aFemale10aFoot10aLeprostatic Agents10aleprosy10aLiver10aMice10aMice, Inbred BALB C10aMycobacterium leprae10aOfloxacin10aRifabutin10aRifampin1 aDhople A M1 aIbanez M A00aIn vivo susceptibility of Mycobacterium leprae to ofloxacin either singly or in combination with rifampicin and rifabutin. Anti-leprosy activity of ofloxacin and ansamycins in mice.  a563-50 v443 a<p>The antimicrobial effects of ofloxacin against Mycobacterium leprae, either alone or in combination with rifampicin and rifabutin, were studied using mouse foot pad assay technique. When used singly, the minimum concentrations of the drugs needed to completely inhibit the growth of Mycobacterium leprae in foot pads of mice were 50 mg/kg body weight for ofloxacin and 0.003% and 0.0001%, respectively, for rifampicin and rifabutin. However, excellent synergistic effects were observed when mice were fed with 25 mg/kg body weight of ofloxacin along with 0.00003% rifabutin, but not rifampicin. Thus, incorporation of ofloxacin and rifabutin in the multiple drug therapy of leprosy patients is suggested.</p>  a0004-4172